BOSTON, April 13, 2015 /PRNewswire/ -- PAREXEL International (NASDAQ: PRXL), a leading global biopharmaceutical services organization, today announced that it has been awarded a 2015 Gold Quill Merit Award from the International Association of Business Communicators (IABC). The award recognizes the Company for developing creative, engaging digital communications with messaging that effectively reaches target audiences.
"Winning a Gold Quill Merit Award is a prestigious recognition of our digital communication efforts," said Diana Martin, Vice President and Global Head of Corporate Communications, PAREXEL. "The Company offers a broad and innovative portfolio of products and services, and we are focused on clearly and consistently communicating these offerings for the benefit of our clients. As a result, PAREXEL.com has become the most visited website among all contract research organizations."
In 2014, PAREXEL launched a new corporate branding initiative based on a commitment to excellence in meeting customer needs: "Your Journey. Our Mission.™" To support that effort, the Company developed a new corporate website and four targeted social media properties on LinkedIn, Twitter, YouTube, and Facebook.
"Our clinical research, consulting and technology customers are increasingly seeking information about PAREXEL through online vehicles," said Mark Anderson, Global Director, Digital Communications, PAREXEL. "In addition, they want to find that information quickly and easily. We've created customer-centric content and digital properties that address that need."
About IABC and the Gold Quill Awards Program
IABC is comprised of more than 12,000 members in 100 chapters worldwide, with awards programs at the chapter, region, and international level. For more than 40 years, IABC's Gold Quill Awards have recognized and awarded excellence in strategic communication worldwide. IABC Gold Quill honors the dedication, innovation and passion of communicators on a global scale. Since 2008, more than 5,000 projects have been entered in the Gold Quill Awards. The IABC Gold Quill Awards program recognizes business communication excellence globally, and is acknowledged as one of the most prestigious awards programs in the industry. The IABC 2015 Gold Quill Awards will be presented at IABC's World Conference, to be held in San Francisco, 14-17 June. More information on World Conference is available at: http://wc.iabc.com/.
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of expertise-based contract research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. PAREXEL Informatics, Inc. provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 81 locations in 51 countries around the world, and has approximately 16,530 employees. For more information about PAREXEL International visit www.PAREXEL.com.
PAREXEL, PAREXEL Informatics, and Your Journey. Our Mission. are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates. All other trademarks are the property of their respective owners.
This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "should," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ materially from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions, and to integrate newly acquired businesses including the acquisition of ClinIntel Limited, or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of foreign currency exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended December 31, 2014 as filed with the Securities and Exchange Commission on February 5, 2015, which "Risk Factors" discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.
Diana Martin, PAREXEL International
Tel: +1 781-434-5516
Email: [email protected]
Cristi Barnett, PAREXEL International
Tel.: +1 781-434-4019
Email: [email protected]
 Source: Alexa.com
SOURCE PAREXEL International Corporation